Increased parathyroid hormone-related peptide in patients with hypercalcemia associated with islet cell carcinoma

Objective: To report the high prevalence of increased parathyroid hormone-related peptide (PTHrP) in patients with islet cell carcinoma and associated hypercalcemia, Design: We conducted a retrospective study of PTHrP levels in patients with hypercalcemia and eucalcemia associated with islet cell carcinoma and compared these findings with those in healthy subjects, Material and Methods: Using a sensitive PTHrP immunochemiluminometric assay, me measured PTHrP levels in 17 patients with islet cell carcinoma and 110 healthy subjects, The differences between PTHrP levels in patients with normal and those with high serum calcium concentrations were analyzed statistically, Results: PTHrP levels were significantly higher (P<0.01) in 10 patients with hypercalcemia and islet cell carcinoma (median, 14.0 pmol/L; range, undetectable to 40.1) than in 7 patients with eucalcemia and islet cell carcinoma (median, undetectable; range, undetectable to 1.3 pmol/L) or in the 110 healthy subjects (median, undetectable; range, undetectable to 4.2 pmol/L). The range of increased PTHrP levels in hypercalcemic islet cell carcinoma was 2 to 20 times the upper normal limit (2.0 pmol/L), Decreased PTHrP and serum calcium and increased parathyroid hormone levels were demonstrated in two patients after effective therapy, For all seven eucalcemic patients with islet cell carcinoma, PTHrP levels did not differ significantly from those in healthy subjects, Conclusion: PTHrP levels are increased in a substantial proportion of patients with hypercalcemia and islet cell carcinoma and seem to decrease after treatment of the underlying tumor, Measurement of PTHrP levels may be useful for confirming the diagnosis of hypercalcemia associated with malignant disease and for monitoring of therapy.